PLAU, an enzyme involved in degrading the extracellular matrix to promote the invasion of tumor cells, has shown promise as a potential target for inhibitors such as amiloride (used for hypertension and heart failure), mexiletine (for treating ventricular arrhythmias), and 4-Chlorophenylguanidine (affecting ion channels) [230]. This evidence concerns the gene PLAU and heart failure.